Meeting
2021 ASCO Annual Meeting
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
Presenter
Stéphane Champiat, MD, PhD
Gustave Roussy Cancer Campus, Department of Drug Development (DITEP)
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Clinical Trial Registration Number
NCT03990233
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2623)
DOI
10.1200/JCO.2021.39.15_suppl.2623
Abstract #
2623
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
Speaker: Angela Tatiana Alistar, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).
Speaker: Emerson A. Lim, MD, MS
Speaker: Saad Zafar Usmani, MD, FACP
Videos & Slides
2016 Palliative and Supportive Care in Oncology Symposium
Wit, Hex, Vin, Life, Death: Using Wit as a Teaching Tool
Speaker: Margaret Edson